SCHEDULE 13G
Amendment No. 1
Human Genome Sciences Incorporated
common stock
Cusip # 444903108
Cusip # 444903108
Item 1: Reporting Person - FMR Corp.
Item 4: Commonwealth of Massachusetts
Item 5: 123,800
Item 6: 0
Item 7: 2,067,557
Item 8: 0
Item 9: 2,326,207
Item 11: 10.11%
Item 12: HC
Cusip # 444903108
Item 1: Reporting Person - Edward C. Johnson 3d
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 2,326,207
Item 8: 0
Item 9: 2,326,207
Item 11: 10.11%
Item 12: IN
Cusip # 444903108
Item 1: Reporting Person - Abigail P. Johnson
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 2,326,207
Item 8: 0
Item 9: 2,326,207
Item 11: 10.11%
Item 12: IN
Cusip # 444903108
Item 1: Reporting Person - Fidelity International Limited
Item 4: Bermuda
Item 5: 258,650
Item 6: 0
Item 7: 258,650
Item 8: 0
Item 9: 2,326,207
Item 11: 10.11%
Item 12: HC
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Item 1(a). Name of Issuer:
Human Genome Sciences Incorporated
Item 1(b). Name of Issuer's Principal Executive Offices:
9410 Key West Avenue,
Rockville, MD 20850-3331
Item 2(a). Name of Person Filing:
FMR Corp.
Item 2(b). Address or Principal Business Office or, if None,
Residence:
82 Devonshire Street, Boston, Massachusetts 02109
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
common stock
Item 2(e). CUSIP Number:
444903108
Item 3. This statement is filed pursuant to Rule 13d-1(c).
Not applicable
Item 4. Ownership
(a) Amount Beneficially Owned:
2,326,207
(b) Percent of Class:
10.11%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
382,450
(ii) shared power to vote or to direct the vote:
0
(iii) sole power to dispose or to direct the
disposition of: 2,326,207
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Common Stock.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Various persons have the right to receive or the
power to direct the receipt of dividends from, or
the proceeds from the sale of, the common stock of
Human Genome Sciences Incorporated. No one person's
interest in the common stock of Human Genome
Sciences Incorporated is more than five percent of
the total outstanding common stock.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company.
See attached Exhibit(s) A, B, and C.
Item 8. Identification and Classification of Members of the
Group.
Not Applicable. See attached Exhibit A.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to
above were not acquired and are not held for the
purpose of or with the effect of changing or
influencing the control of the issuer of the
securities and were not acquired and are not held in
connection with or as a participant in any
transaction having that purpose or effect.
Signature
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information
set forth in this Schedule 13G in connection with
FMR Corp.'s beneficial ownership of the common stock
of Human Genome Sciences Incorporated at September
27, 1999 is true, complete and correct.
October 1, 1999
Date
Signature
Eric D. Roiter
Duly authorized under
Power of Attorney
dated December 30, 1997,
by and on behalf
of FMR Corp. and its
direct and indirect
subsidiaries.
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Pursuant to the instructions in Item 7 of Schedule 13G,
Fidelity Management & Research Company ("Fidelity"), 82
Devonshire Street, Boston, Massachusetts 02109, a wholly-owned
subsidiary of FMR Corp. and an investment adviser registered
under Section 203 of the Investment Advisers Act of 1940, is the
beneficial owner of 1,887,057 shares or 8.20% of the common stock
outstanding of Human Genome Sciences Incorporated ("the Company")
as a result of acting as investment adviser to various investment
companies (the "funds") registered under Section 8 of the
Investment Company Act of 1940. The number of shares of common
stock of Human Genome Sciences Incorporated owned by the
investment companies at September 27, 1999 included 32,567 shares
of common stock resulting from the assumed conversion of
$1,700,000 principal amount of HUMAN GENOME 5.5% 7/01/06 144A
(19.1571 shares of common stock for each $1,000 principal amount
of debenture).
Edward C. Johnson 3d, FMR Corp., through its control of
Fidelity, and the funds collectively each has sole power to
dispose of the 1,887,057 shares owned by the Funds.
Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR
Corp., has the sole power to vote or direct the voting of the
shares owned directly by the funds, which power resides with the
funds' Boards of Trustees. Fidelity carries out the voting of
the shares under written guidelines established by the funds'
Boards of Trustees.
Fidelity Management Trust Company, 82 Devonshire Street,
Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR
Corp. and a bank as defined in Section 3(a)(6) of the Securities
Exchange Act of 1934, is the beneficial owner of 180,500 shares
or 0.78% of the common stock outstanding of the Company as a
result of its serving as investment manager of the institutional
account(s).
Edward C. Johnson 3d and FMR Corp., through its control of
Fidelity Management Trust Company, each has sole dispositive
power over 180,500 shares and sole power to vote or to direct the
voting of 123,800 shares.
Members of the Edward C. Johnson 3d family are the
predominant owners of Class B shares of common stock of FMR
Corp., representing approximately 49% of the voting power of FMR
Corp. Mr. Johnson 3d owns 12.0% and Abigail Johnson owns 24.5%
of the aggregate outstanding voting stock of FMR Corp. Mr.
Johnson 3d is Chairman of FMR Corp. and Abigail P. Johnson is a
Director of FMR Corp. The Johnson family group and all other
Class B shareholders have entered into a shareholders' voting
agreement under which all Class B shares will be voted in
accordance with the majority vote of Class B shares.
Accordingly, through their ownership of voting common stock and
the execution of the shareholders' voting agreement, members of
the Johnson family may be deemed, under the Investment Company
Act of 1940, to form a controlling group with respect to FMR
Corp.
Fidelity International Limited, Pembroke Hall, 42 Crowlane,
Hamilton, Bermuda, and various foreign-based subsidiaries provide
investment advisory and management services to a number of non-
U.S. investment companies and certain institutional investors.
Fidelity International Limited is the beneficial owner of 258,650
shares or 1.12% of the common stock outstanding of the Company.
Additional information with respect to the beneficial ownership
of Fidelity International Limited is shown on Exhibit B.
EXHIBIT to SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Pursuant to instructions in Item 7 of Schedule 13G, this
Exhibit has been prepared to identify Fidelity International
Limited, Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda, a
Bermudan joint stock company incorporated for an unlimited
duration by private act of the Bermuda Legislature (FIL) and an
investment adviser to various investment companies (the
"International Funds") and certain institutional investors, as a
beneficial owner of the 258,650 shares or 1.12% of the common
stock outstanding of Human Genome Sciences Incorporated.
Prior to June 30, 1980, FIL was a majority-owned subsidiary
of Fidelity Management & Research Company (Fidelity), a wholly-
owned subsidiary of FMR Corp. On that date, the shares of FIL
held by Fidelity were distributed, as a dividend, to the
shareholders of FMR Corp. FIL currently operates as an entity
independent of FMR Corp. and Fidelity. The International Funds
and FIL's other clients, with the exception of Fidelity and an
affiliated company of Fidelity, are non-U.S. entities.
A partnership controlled by Edward C. Johnson 3d and members
of his family owns shares of FIL voting stock with the right to
cast approximately 39.89% of the total votes which may be cast by
all holders of FIL voting stock. Mr. Johnson 3d is Chairman of
FMR Corp. and FIL. FMR Corp. and FIL are separate and
independent corporate entities, and their Boards of Directors are
generally composed of different individuals. Other than when one
serves as a sub adviser to the other, their investment decisions
are made independently, and their clients are generally different
organizations.
FMR Corp. and FIL are of the view that they are not acting as
a "group" for purposes of Section 13(d) under the Securities
Exchange Act of 1934 (the "1934" Act) and that they are not
otherwise required to attribute to each other the "beneficial
ownership" of securities "beneficially owned" by the other
corporation within the meaning of Rule 13d-3 promulgated under
the 1934 Act. Therefore, they are of the view that the shares
held by the other corporation need not be aggregated for purposes
of Section 13(d). However, FMR Corp. is making this filing on a
voluntary basis as if all of the shares are beneficially owned by
FMR Corp. and FIL on a joint basis.
FIL has sole dispositive power over 258,650 shares owned by
the International Funds. FIL has sole power to vote or direct the
voting of 258,650 shares of common stock held by the
International Funds as reported above.
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
RULE 13d-1(f)(1) AGREEMENT
The undersigned persons, on October 1, 1999, agree and
consent to the joint filing on their behalf of this Schedule 13G
in connection with their beneficial ownership of the common stock
of Human Genome Sciences Incorporated at September 27, 1999.
FMR Corp.
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of
Attorney
dated December 30, 1997, by and on
behalf
of FMR Corp. and its direct and
indirect
subsidiaries.
Edward C. Johnson 3d
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of
Attorney
dated December 30, 1997, by and on
behalf
of Edward C. Johnson 3d.
Abigail P. Johnson
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of
Attorney
dated December 30, 1997, by and on
behalf
of Abigail P. Johnson.
Fidelity Management & Research
Company
By /s/Eric D. Roiter
Eric D. Roiter
Senior V.P. and General Counsel
